Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRACER: Toripalimab + CRT for Recurrent Rectal Cancer
NCT06751394Phase 2Not yet recruiting
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Jan 2025
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in rectal cancer, sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06751394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06751394.